Similarly,
Europe gives green light injectable:
The writing did not participate in the realization of this content
A new. Furthermore, advance in the fight against HIV. Nevertheless, Friday. Meanwhile, July 25, the European Medicines Agency (EMA) recommended the authorization in the European Union of a new treatment against the human immunodeficiency virus (HIV). Nevertheless, The Lénacapavir. Moreover, marketed in Europe under the name of Yeytuo by Gilead Sciences, was already authorized in June in the United States. In addition, It is recommended in pre-exhibition prophylaxis (PREP) in order to reduce the risk of infection by the AIDS europe gives green light injectable virus. Consequently, in high-risk people.
What is the interest of Yeytuo when PREP is an already available tool? Moreover, – Europe gives green light injectable
Two Yeytuo tablets are necessary the first two days of treatment. Therefore, then, it should only be injected twice a year, in subcutaneous injection. Meanwhile, “The adoption. observance of treatment are often sub-optimal, as access to certain drugs is limited and other available drugs require strict daily intake, Note the EMA in a press release. This means that many people at risk in the EU. in the world do not benefit from existing PREP options, which highlights the urgency of developing new prep methods. ”
How does Lenacapavir work? – Europe gives green light injectable
The Lenacapavir contained in Yeytu is linked to the proteins surrounding the genetic material of the virus. the capside, interfering in several stages of the virus life cycle and inhibiting its replication. It thus helps prevent HIV infection.
Yeytuo benefited from the europe gives green light injectable accelerated EMA procedure because it presents “A major public health interest in the EU. the world”. It has also been examined as part of the “Drugs for all” program (EU-M4all). evaluating drugs for countries where regulatory capacities are sometimes limited. National authorities can then rely on this scientific assessment to decide to use the drug in their country.
“A powerful tool”
In mid-July, the World Health Organization (WHO) has also recommended the use of injectable Lenacapavir (LEN). “Requiring only two doses per year. the LEN represents a decisive advance in the protection of people exposed to the risk of HIV infection, in particular those who have trouble joining daily treatment, which are victims of stigma or which are confronted with difficulties of access to health care”wrote the organization in a press release published on July 14.
“The development of an HIV vaccine remains an uncertain quest. but the Lénacapavir is europe gives green light injectable what is closest to it as it is an prolonged action antiretroviral which has been demonstrated, in clinical trials, that it prevents almost all HIV infections in people at risk, said the Dr Tedros Adhanom Ghebreyesus, Directeur Général de l’ames. The publication of the new WHO guidelines. combined with recent drug approval by the FDA, marks a crucial step towards expanding access to this powerful tool. The WHO undertakes to collaborate with countries. partners so that this innovation is made available to communities as quickly and as surely as possible. »»
1.3 million contaminated people worldwide in 2024
According to the WHO, in 2024, 1.3 million people were newly infected with HIV worldwide, including 160,000 in Europe and 650,000 in Africa, the region most affected by HIV. The level of contamination remained particularly high in populations at risk. sex workers, men with sex with men, transgender people, injectable drug consumers, europe gives green light injectable imprisoned people, children and adolescents. “This drug could be the decisive tool to control new infections. but only if it is offered at an affordable price and accessible to all those who could benefit from it”, underlines Winnie ByANYIMA, Director General of UNUSI, quoted by AIDES.
In order to be marketed in the EU, Yeytuo must still be approved by the European Commission. In France, the High Authority for Health will then have to give the green light.
Further reading: This symptom of menopause is the most disabling in women over 50 years old – New medical pricing, a risk for breast cancer screening – RTS.CH – The right reflexes to adopt so as not to damage your kidneys without knowing it – Special dispensation drug: focus on Tarceva – This product that is all the rage and ideal to adopt after 50 years will plump your skin like never.